US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
pharma · Esophageal Squamous Cell Carcinoma
Sichuan University
Sichuan University drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 4
- Patents
- 0
Sichuan University pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sichuan University drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Sichuan University in public FDA and regional records.
-
Development asset linked to Sichuan University in public FDA and regional records.
-
Development asset linked to Sichuan University in public FDA and regional records.